CAPLIN POINT LABORATORIES LTD.

Caplin Point Laboratories Ltd has announced the closure of its trading window from July 01, 2026. This closure is in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The trading window will remain shut for the finalization of the unaudited financial results for the quarter ending June 30, 2026. It is set to reopen 48 hours after the declaration of these financial results to the stock exchanges. This measure is standard practice to prevent insider trading during sensitive financial reporting periods.

Caplin Point Laboratories' subsidiary, Caplin Steriles Limited, received final approval from the USFDA for its ANDA Foscarnet Sodium Injection (6000 mg/250 mL Infusion Bag), a generic version of Foscavir Injection from Clinigen Healthcare Ltd. The drug, an antiviral medication, is used to treat CMV retinitis in AIDS patients and HSV infection in immunocompromised individuals. US sales for Foscarnet Sodium Injection were approximately $15 million for the 12 months ending March 2026, according to IQVIA (IMS Health).

Caplin Point Laboratories Ltd's board, in its meeting on May 14, 2026, declared an interim dividend of ₹4.00 (200%) per equity share for the financial year 2025-26. The record date for determining shareholders' eligibility for the dividend is set as May 30, 2026. The board also approved the audited standalone and consolidated financial results for the year ended March 31, 2026, and amendments to the Code of Practices and Procedure for Fair Disclosure of Unpublished Price Sensitive Information.

Caplin Point Laboratories Ltd's board approved the audited standalone and consolidated financial results for the year ended March 31, 2026. An interim dividend of ₹4.00 (200%) per equity share with a face value of ₹2 was declared, with May 30, 2026, set as the record date. The board also approved amendments to the Code of Practices and Procedure for Fair Disclosure of Unpublished Price Sensitive Information. The auditors, M/s Brahmayya & Co, issued an unmodified opinion on the financial statements.

Caplin Point Laboratories Ltd's board approved the audited standalone and consolidated financial results for the year ended March 31, 2026. An interim dividend of ₹4.00 (200%) per equity share with a face value of ₹2 each was declared, with May 30, 2026, set as the record date. The board also approved amendments to the Code of Practices and Procedure for Fair Disclosure of Unpublished Price Sensitive Information. The auditor's report from M/s Brahmayya & Co, Chartered Accountants, issued an unmodified opinion on the financial statements.

Caplin Point Laboratories Ltd has scheduled a Board of Directors meeting on May 14, 2026, to consider and approve the audited financial results for the year ended March 31, 2026 (standalone & consolidated). The board will also consider the declaration of an interim dividend, if any, for FY 2025-26 and the fixation of a record date. The trading window for designated persons remains closed until May 16, 2026.

Caplin Point Laboratories' subsidiary, Caplin Steriles Limited, received final approval from the USFDA for its ANDA Calcium Gluconate Injection USP. The injection, a generic version of Fresenius Kabi USA, LLC's drug, is indicated for treating acute symptomatic hypocalcemia in pediatric and adult patients. The US sales for Calcium Gluconate Injection USP were approximately $71 million for the 12 months ending March 2026, according to IQVIA (IMS Health).

Caplin Point Laboratories Ltd, in accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015 and the company's Code of Conduct, has announced the closure of the Trading Window for dealing in the securities of the company. The closure will commence from April 01, 2026, and is in connection with the finalization of audited Financial Statements/ Financial Results for the year ending March 31, 2026. The Trading Window will reopen 48 hours after the Financial Results are declared to the Stock Exchanges.

Caplin Steriles Limited, a subsidiary of Caplin Point Laboratories Limited, has received final approval from the USFDA for its Abbreviated New Drug Application (ANDA) Potassium Phosphates Injection USP. This injection is a generic therapeutic equivalent version of the Reference Listed Drug (RLD) from Fresenius Kabi USA, LLC. The injection is used as a source of phosphorus in intravenous fluids to correct hypophosphatemia and as parenteral nutrition in adults and pediatric patients who cannot take oral supplements. According to IQVIA™, the injection had US sales of approximately $57 million for the 12-month period ending January 2026.

Caplin Steriles Limited, a subsidiary of Caplin Point Laboratories Limited, has received final approval from the USFDA for its Abbreviated New Drug Application (ANDA) Desmopressin Acetate Injection USP, 4 mcg/mL single-dose vials and 40 mcg/10 mL (4 mcg/mL) multiple-dose vials. This is a generic therapeutic equivalent version of the Reference Listed Drug (RLD) DDAVP (desmopressin acetate) Injection, 4 mcg/mL of Nordic Pharma Inc. The injection is used to treat conditions like haemophilia A, von Willebrand disease, and central diabetes insipidus. According to IQVIA™, the US sales for this injection were approximately $26 million for the 12-month period ending December 2025.